Evicenter
MarkdownMedical informationP&T meetings
Lysergide (DT120)

Generalized anxiety disorder

Also known as MM120
Launch
Not announced
Last updated
199 sources

Section 1 of 6

Terms and abbreviations

1 evidence topic · 0 sources

AbbreviationTerm
5-HT5-hydroxytryptamine (serotonin)
5-HT1ASerotonin 1A receptor
5-HT2ASerotonin 2A receptor
5-HT2BSerotonin 2B receptor
5-HT2CSerotonin 2C receptor
5D-ASC5 Dimensions of Altered States of Consciousness questionnaire
AAFPAmerican Academy of Family Physicians
ADAnxiety disorders
AEAdverse event
AESIAdverse event of special interest
AFPAmerican Family Physician
AGSAmerican Geriatrics Society
AHAntihistamines
AHFSAmerican Hospital Formulary Service
ANCOVAAnalysis of covariance
ANOVAAnalysis of variance
AOOAge of onset
APAAmerican Psychiatric Association
ASEXArizona Sexual Experiences Scale
ASIRAge-standardized incidence rate
ASPRAge-standardized prevalence rate
AUCArea under the concentration-time curve
AZAAzapirones
BAIBeck Anxiety Inventory
BAPBritish Association for Psychopharmacology
BDIBeck Depression Inventory
BLABasolateral amygdala
BMIBody mass index
BPBlood pressure
BZBenzodiazepines
C-SSRSColumbia-Suicide Severity Rating Scale
CAMComplementary and alternative medicine
CANMATCanadian Network for Mood and Anxiety Treatments
CBTCognitive behavioral therapy
CFRCode of Federal Regulations
CGI-IClinical Global Impression-Improvement
CGI-SClinical Global Impression-Severity
CHDCoronary heart disease
CIConfidence interval
CLBPChronic low back pain
CMACentromedial amygdala
CMSCenters for Medicare & Medicaid Services
CNSCentral nervous system
COICost of illness
CPTCurrent Procedural Terminology
CRControlled release
CrICredible interval
CSAControlled Substances Act
CSFQ-14Changes in Sexual Functioning Questionnaire, short form
CTISClinical Trials Information System
CYPCytochrome P450
CYP2D6Cytochrome P450 2D6
DEADrug Enforcement Administration
DPNPDiabetic peripheral neuropathic pain
DSMDosing session monitor
DSM-5Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition
DSM-IVDiagnostic and Statistical Manual of Mental Disorders, Fourth Edition
EMAEuropean Medicines Agency
EOP2End-of-phase 2
EoSCEnd-of-session checklist
EQ-5D-5LEuroQol 5-Dimension 5-Level questionnaire
ERExtended release
ESEffect size
EUEuropean Union
FASFull analysis set
FDAU.S. Food and Drug Administration
FMFibromyalgia
GADGeneralized anxiety disorder
GAD-7Generalized Anxiety Disorder 7-item scale
GHCGeneral health component
GMRGeometric mean ratio
GSIGlobal Severity Index
HAM-AHamilton Anxiety Rating Scale
HAM-DHamilton Depression Rating Scale
HCPHealthcare provider
HCPCSHealthcare Common Procedure Coding System
HCRUHealthcare resource utilization
HPPDHallucinogen persisting perception disorder
HRHazard ratio
HRAHealth Research Authority
HRQoLHealth-related quality of life
ICD-10International Classification of Diseases, 10th Revision
ICERInstitute for Clinical and Economic Review; incremental cost-effectiveness ratio
IDRIncidence density ratio
ILAPInnovative Licensing and Access Pathway
INDInvestigational New Drug application
IQRInterquartile range
ISRCTNInternational Standard Randomised Controlled Trial Number registry
ITTIntention to treat
LSLeast squares
LSDLysergic acid diethylamide
LTILife-threatening illness
MADRSMontgomery-Åsberg Depression Rating Scale
MBHRMental and Behavioral Health Registry
MCP-ModMultiple Comparison Procedure-Modelling
MDMean difference
MDDMajor depressive disorder
MDEMajor depressive episode
MDMA3,4-methylenedioxymethamphetamine
MDMA-APMDMA-assisted psychotherapy
MDPSMental and Substance Use Disorders Prevalence Study
MEPSMedical Expenditure Panel Survey
MHCMental health component
MHRAMedicines and Healthcare products Regulatory Agency
MINIMini-International Neuropsychiatric Interview
MIPSMerit-based Incentive Payment System
MMRMMixed-effects model for repeated measures
MRRMortality rate ratio
NCS-ANational Comorbidity Survey Adolescent Supplement
NCS-RNational Comorbidity Survey Replication
NDANew Drug Application
NESARCNational Epidemiologic Survey on Alcohol and Related Conditions
NHISNational Health Interview Survey
NHWSNational Health and Wellness Survey
NICENational Institute for Health and Care Excellence
NNTNumber needed to treat
NSDUHNational Survey on Drug Use and Health
OAOsteoarthritis
OCDObsessive-compulsive disorder
ODTOrally disintegrating tablet
OOPOut-of-pocket
OROdds ratio
PBMPharmacy benefit manager
PDPanic disorder; pharmacodynamics
PGBPregabalin
PGI-CPatient Global Impression of Change
PGI-SPatient Global Impression of Severity
PHCPhysical health component
PKPharmacokinetics
PMPoor metabolizer
PPSPer protocol set
PTSDPosttraumatic stress disorder
QALYQuality-adjusted life year
QHPQualified healthcare professional
QTcCorrected QT interval
RCTRandomized controlled trial
REMSRisk Evaluation and Mitigation Strategy
RMPRisk Management Plan
RRRelative risk
RVURelative value unit
SADSocial anxiety disorder
SAESerious adverse event
SAFSafety set
SCIDStructured Clinical Interview for DSM
SCL-90-RSymptom Checklist-90-Revised
SDStandard deviation
SDSSheehan Disability Scale
SEStandard error
SISuicidal ideation
SMDStandardized mean difference
SNRISerotonin-norepinephrine reuptake inhibitor
SSRESample size re-estimation
SSRISelective serotonin reuptake inhibitor
STAIState-Trait Anxiety Inventory
STAI-GState-Trait Anxiety Inventory, global score
TAUTreatment as usual
TCATricyclic antidepressant
TEAETreatment-emergent adverse event
TQTThorough QT
TRDTreatment-resistant depression
UCUsual care
UHBUniversity Hospital Basel
UIUncertainty interval
UKUnited Kingdom
UMUltra-rapid metabolizer
USUnited States
USANUnited States Adopted Name
USPSTFU.S. Preventive Services Task Force
VASVisual analog scale
WFSBPWorld Federation of Societies of Biological Psychiatry
WLWaitlist
WPAI-SHPWork Productivity and Activity Impairment Questionnaire: Specific Health Problem
XRExtended release